Please assess the completion status of the following clinical trial:

Trial Title: S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage III or IV Hodgkin's disease with at least 3 of the following characteristics:~  * Albumin less than 4.0 mg/dL~ * Hemoglobin less than 10.5 g/dL~ * Leukocytosis at least 15,000/mm\^3~ * Lymphocytopenia less than 600/mm\^3 or less than 8% of total WBC~ * Male sex~ * At least 45 years of age~ * Stage IV disease~* Bidimensionally measurable disease~* Bilateral or unilateral bone marrow aspiration and biopsy performed within 42 days of study~* Negative chest x-ray within 42 days of study OR~* Chest x-ray performed within 28 days of study~* Negative CT scan of thorax, abdomen, and pelvis within 42 days of study OR~* CT scan of thorax, abdomen, and pelvis performed within 28 days of study~* No history of lymphoma, myelodyplastic syndrome, or leukemia~* No CNS involvement by Hodgkin's disease~PATIENT CHARACTERISTICS:~Age:~* 15 to 65~Performance status:~* Zubrod 0-1~Life expectancy:~* Not specified~Hematopoietic:~* See Disease Characteristics~Hepatic:~* See Disease Characteristics~* Bilirubin no greater than 1.5 times upper limit of normal (ULN) (unless elevation due to liver infiltration by Hodgkin's disease)~* Lymphoma-related hepatic dysfunction allowed~Renal:~* Creatinine no greater than 2.0 times ULN~* Creatinine clearance at least 60 mL/min~* Lymphoma-related renal dysfunction allowed~Cardiovascular:~* No coronary artery disease, cardiomyopathy, congestive heart failure, or arrhythmias requiring therapy~* Ejection fraction normal~* No significant EKG abnormalities suggesting active cardiac disease~Pulmonary:~* Corrected DLCO at least 60% OR~* FEV1 at least 60% predicted~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No HIV or AIDS~* No other prior malignancy within past 5 years except adequately treated basal cell or squamous cell skin cancer~* No active bacterial, fungal, or viral infection\*~* Afebrile for 3 consecutive days\* NOTE: \*Prior to randomization portion of study~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy for Hodgkin's disease except single course of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) within 35 days of study~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy for Hodgkin's disease~Surgery:~* Not specified~Other:~* At least 3 days since prior antibiotics, antifungals, or antivirals (except for prophylactic therapy or fever associated with underlying lymphoma) (for randomization portion of study)

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ABVD x 5 + ABVD x 3 (Type: ACTIVE_COMPARATOR): Patients receive 5 28-day cycles of ABVD (doxorubicin 25 mg/m\^2, bleomycin 10 U/m\^2, vinblastine 6 mg/m\^2, dacarbazine 375 mg/m\^2 all on days 1 and 15). Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
- ABVD x 5 + ABVD x 1 + HDT + PBSCT (Type: EXPERIMENTAL): Patients receive 5 28-day cycles of ABVD (doxorubicin 25 mg/m\^2, bleomycin 10 U/m\^2, vinblastine 6 mg/m\^2, dacarbazine 375 mg/m\^2 all on days 1 and 15). Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant. Patients randomized to the transplant arm have 2 x 10\^6 CD34+ blood mononuclear cells/kg of actual body weight collected at day -7. High dose therapy consists of BCNU 150/m\^2 on days -6 to -4, etoposide 60 mg/kg on day -4, and cyclophosphamide 100 mg/kg on day -2. Peripheral blood stem cells are infused on day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).